News

Find News

Filter articles

Applied Filters

Showing 1 to 10 of 778 results

Indivior appeal fails to stop generic opioid addiction challenge

US15-07-2019Saman Javed

The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

German Court rules Sanofi’s Praluent infringes Amgen patent

Germany12-07-2019

A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

US12-07-2019Sarah Morgan

Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

US05-07-2019

US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.

UKIPO seeks no-deal Brexit SPC comments

EU, UK05-07-2019

The UK Intellectual Property Office has today, July 5, opened a consultation into supplementary protection certificate law in the event of a ‘no deal’ Brexit.

SPC generics waiver comes into force

EU01-07-2019

The controversial supplementary protection certificate manufacturing waiver has come into force today, July 1.

Novartis secures injunction barring generic MS drugs

US26-06-2019

A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis drug Gileyna.

Teva infringed UCB patent, rules Fed Circuit

US25-06-2019

The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.

Fed Circuit sides with Merck in antifungal treatment dispute

US25-06-2019

A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.

Generic drugs cost 30x more in poor countries: report

India, US, Zimbabwe20-06-2019

Generic medicines can cost up to 30 times more in poor countries, according to a new study.

Showing 1 to 10 of 778 results

LSIPR